Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MARLOWE PLC AGM Information 2018

Sep 5, 2018

7777_dva_2018-09-05_0690270b-f8e3-4440-b987-5cf2d0c37b48.html

AGM Information

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8528Z

Marlowe PLC

05 September 2018

5 September 2018

Marlowe plc

Result of Annual General Meeting

Marlowe plc, the support services group focused on acquiring and developing companies that provide critical testing and maintenance services, announces that, at its Annual General Meeting held today, all resolutions were duly passed.

For further information:

Marlowe plc www.marloweplc.com
Alex Dacre, Chief Executive Tel: +44 (0) 203 841 6194
Mark Adams, Group Finance Director [email protected]
Cenkos Securities plc (Nominated Adviser and Broker)
Nicholas Wells Tel: +44 (0)20 7397 8900
FTI Consulting
Nick Hasell Tel: +44 (0)20 3727 1340
Alex Le May

About Marlowe plc

Marlowe is an AIM-listed company formed to create sustainable shareholder value through the acquisition and development of businesses that provide critical testing & maintenance services in the UK.  It is focused on fire protection, security systems, water treatment and air quality services - which are essential to its customers' operations and invariably governed by regulation, and where customers require a single specialist outsourced provider with nationwide coverage. Our customers can be found on most high streets, in office complexes and industrial estates, and include SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

RAGLIFSAAEIEIIT